Successfully reported this slideshow.
We use your LinkedIn profile and activity data to personalize ads and to show you more relevant ads. You can change your ad preferences anytime.

Amyotrophic Lateral Sclerosis (ALS) Therapeutics - Pipeline Assessment and Market Forecasts to 2018

176 views

Published on

Amyotrophic Lateral Sclerosis (ALS) Therapeutics - Pipeline Assessment and Market Forecasts to 2018SummaryGlobalData, the industry analysis specialist, has released its new report, 'Amyotrophic Lateral Sclerosis (ALS) Therapeutics - Pipeline Assessment and Market Forecasts to 2018'. The report is an essential source of information and analysis on the global Amyotrophic Lateral Sclerosis Therapeutics market. The report identifies the key trends shaping and driving the global Amyotrophic Lateral Sclerosis Therapeutics market. The report also provides insights on the prevalent competitive landscape and the emerging players expected to significantly alter the market positioning of the current market leaders. Most importantly, the report provides valuable insights on the pipeline products within the global Amyotrophic Lateral Sclerosis Therapeutics sector. This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GlobalData's team of industry experts.ScopeThe report provides information on the key drivers and challenges of the Amyotrophic Lateral Sclerosis Therapeutics market. Its scope includes - - Annualized seven key markets (US, France, Germany, Italy, Spain, UK and Japan) Amyotrophic Lateral Sclerosis Therapeutics market revenues data from 2005 to 2009, forecast for eight years to 2017. - Pipeline analysis data providing a split across the different phases, mechanisms of action being developed and emerging trends by seven key markets. Pipeline candidates fall under major therapeutic classes.- Analysis of the current and future competition in the seven key countries Amyotrophic Lateral Sclerosis Therapeutics market. - Insightful review of the key industry drivers, restraints and challenges. Each trend is independently researched to provide a qualitative analysis of its implications. - Key topics covered include strategic competitor assessment, market characterization, unmet needs and the implications for the Amyotrophic Lateral Sclerosis Therapeutics market.- Analysis of key recent licensing and partnership agreements in Amyotrophic Lateral Sclerosis Therapeutics market Reasons to buyThe report will enhance your decision making capability. It will allow you to - - Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies and by identifying the companies with the most robust pipeline. - Develop business strategies by understanding the trends shaping and driving the global Amyotrophic Lateral Sclerosis Therapeutics market. - Drive revenues by understanding the key trends, innovative products and technologies, market segments and companies likely to impact the global Amyotrophic Lateral Sclerosis Therapeutics market in future. - Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of various competitors. - Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage. - Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments and strategic partnerships. - What's the next big thing in the global Amyotrophic Lateral Sclerosis Therapeutics market landscape' ' Identify, understand and capitalize.

  • Hi! Get Your Professional Job-Winning Resume Here! 👉 http://bit.ly/rexumtop
       Reply 
    Are you sure you want to  Yes  No
    Your message goes here
  • Be the first to like this

Amyotrophic Lateral Sclerosis (ALS) Therapeutics - Pipeline Assessment and Market Forecasts to 2018

  1. 1. Find Industry reports, Company profilesReportLinker and Market Statistics >> Get this Report Now by email!Amyotrophic Lateral Sclerosis (ALS) Therapeutics - PipelineAssessment and Market Forecasts to 2018Published on September 2011 Report SummaryAmyotrophic Lateral Sclerosis (ALS) Therapeutics - Pipeline Assessment and Market Forecasts to 2018SummaryGlobalData, the industry analysis specialist, has released its new report, Amyotrophic Lateral Sclerosis (ALS) Therapeutics - PipelineAssessment and Market Forecasts to 2018. The report is an essential source of information and analysis on the global AmyotrophicLateral Sclerosis Therapeutics market. The report identifies the key trends shaping and driving the global Amyotrophic LateralSclerosis Therapeutics market. The report also provides insights on the prevalent competitive landscape and the emerging playersexpected to significantly alter the market positioning of the current market leaders. Most importantly, the report provides valuableinsights on the pipeline products within the global Amyotrophic Lateral Sclerosis Therapeutics sector. This report is built using dataand information sourced from proprietary databases, primary and secondary research and in-house analysis by GlobalDatas team ofindustry experts.ScopeThe report provides information on the key drivers and challenges of the Amyotrophic Lateral Sclerosis Therapeutics market. Itsscope includes -- Annualized seven key markets (US, France, Germany, Italy, Spain, UK and Japan) Amyotrophic Lateral Sclerosis Therapeuticsmarket revenues data from 2005 to 2009, forecast for eight years to 2017.- Pipeline analysis data providing a split across the different phases, mechanisms of action being developed and emerging trends byseven key markets. Pipeline candidates fall under major therapeutic classes.- Analysis of the current and future competition in the seven key countries Amyotrophic Lateral Sclerosis Therapeutics market.- Insightful review of the key industry drivers, restraints and challenges. Each trend is independently researched to provide aqualitative analysis of its implications.- Key topics covered include strategic competitor assessment, market characterization, unmet needs and the implications for theAmyotrophic Lateral Sclerosis Therapeutics market.- Analysis of key recent licensing and partnership agreements in Amyotrophic Lateral Sclerosis Therapeutics marketReasons to buyThe report will enhance your decision making capability. It will allow you to -- Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies and byidentifying the companies with the most robust pipeline.- Develop business strategies by understanding the trends shaping and driving the global Amyotrophic Lateral Sclerosis Therapeuticsmarket.- Drive revenues by understanding the key trends, innovative products and technologies, market segments and companies likely toimpact the global Amyotrophic Lateral Sclerosis Therapeutics market in future.- Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance ofvarious competitors.Amyotrophic Lateral Sclerosis (ALS) Therapeutics - Pipeline Assessment and Market Forecasts to 2018 (From Slideshare) Page 1/8
  2. 2. Find Industry reports, Company profilesReportLinker and Market Statistics >> Get this Report Now by email!- Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitiveadvantage.- Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunitiesfor consolidations, investments and strategic partnerships.- Whats the next big thing in the global Amyotrophic Lateral Sclerosis Therapeutics market landscape Identify, understand andcapitalize. Table of Content1 Table of Contents1 Table of Contents 31.1 List of Tables 51.2 List of Figures 62 Amyotrophic Lateral Sclerosis Therapeutics: Introduction 72.1 Overview 72.2 Epidemiology 82.3 Etiology and Pathophysiology 102.4 Symptoms 102.5 Diagnosis 112.6 Treatment and Management Pattern 122.7 Referral Pathway 162.8 GlobalData Pipeline Report Guidance 173 Amyotrophic Lateral Sclerosis Therapeutics: Market Characterization 183.1 Amyotrophic Lateral Sclerosis Therapeutics Market Size (2005 - 2010) - Global 183.2 Amyotrophic Lateral Sclerosis Therapeutics Market Forecast (2010 - 2018) - Global 193.3 Amyotrophic Lateral Sclerosis Therapeutics Market Size (2005 - 2010): The US 203.4 Amyotrophic Lateral Sclerosis Therapeutics Market Forecast (2010-2018): The US 213.5 Amyotrophic Lateral Sclerosis Therapeutics Market (2005 - 2010): France 223.6 Amyotrophic Lateral Sclerosis Therapeutics Market Forecast (2010 - 2018): France 233.7 Amyotrophic Lateral Sclerosis Therapeutics Market (2005 - 2010): Germany 243.8 Amyotrophic Lateral Sclerosis Therapeutics Market Forecast (2010 - 2018): Germany 253.9 Amyotrophic Lateral Sclerosis Therapeutics Market (2005 - 2010): Italy 263.10 Amyotrophic Lateral Sclerosis Therapeutics Market Forecast (2010 - 2018): Italy 273.11 Amyotrophic Lateral Sclerosis Therapeutics Market (2005 - 2010): Spain 283.12 Amyotrophic Lateral Sclerosis Therapeutics Market Forecast (2010 - 2018): Spain 293.13 Amyotrophic Lateral Sclerosis Therapeutics Market (2005 - 2010): The UK 303.14 Amyotrophic Lateral Sclerosis Therapeutics Market Forecast (2010 - 2018): The UK 313.15 Amyotrophic Lateral Sclerosis Therapeutics Market (2005 - 2010): Japan 323.16 Amyotrophic Lateral Sclerosis Therapeutics Market Forecast (2010 - 2018): Japan 333.17 Drivers and Barriers for the Amyotrophic Lateral Sclerosis Therapeutics Market 343.17.1 Drivers for the Amyotrophic Lateral Sclerosis Therapeutics Market 343.17.2 Barriers for the Amyotrophic Lateral Sclerosis Therapeutics Market 343.18 Opportunity and Unmet Need Analysis 353.19 Key Takeaway 364 Amyotrophic Lateral Sclerosis Therapeutics: Competitive Assessment 374.1 Overview 37Amyotrophic Lateral Sclerosis (ALS) Therapeutics - Pipeline Assessment and Market Forecasts to 2018 (From Slideshare) Page 2/8
  3. 3. Find Industry reports, Company profilesReportLinker and Market Statistics >> Get this Report Now by email!4.2 Strategic Competitor Assessment 374.3 Product Profile for the Major Marketed Products in the Amyotrophic Lateral Sclerosis Therapeutics Market 384.3.1 Rilutek (riluzole) 385 Amyotrophic Lateral Sclerosis Therapeutics: Pipeline Assessment 405.1 Overview 405.2 Strategic Pipeline Assessment 405.3 Amyotrophic Lateral Sclerosis Therapeutics Pipeline Pipeline by Phases of Development 405.3.1 Amyotrophic Lateral Sclerosis Therapeutics Phase III Pipeline 415.3.2 Amyotrophic Lateral Sclerosis Therapeutics Phase II Pipeline 415.3.3 Amyotrophic Lateral Sclerosis Therapeutics Phase I Pipeline 425.3.4 Amyotrophic Lateral Sclerosis Therapeutics Preclinical Pipeline 425.3.5 Amyotrophic Lateral Sclerosis Therapeutics Discovery Pipeline 435.3.6 Amyotrophic Lateral Sclerosis Therapeutics Phase Unknown 435.4 Amyotrophic Lateral Sclerosis Therapeutics Market Pipeline by Mechanism of Action 445.5 Technology Trends Analytical Framework 455.6 ALS Therapeutics Most Promising Drugs Under Development 465.7 Molecule Profile for Promising Drugs under Development 475.7.1 Dexpramipexole (KNS-760704) 475.7.2 Olesoxime (TRO 19622) 495.7.3 Radicut 505.7.4 ALS-02 515.8 Profile for Other Drugs under Clinical Development 525.8.1 E0302 (mecobalamin) 526 Amyotrophic Lateral Sclerosis Therapeutics: Clinical Trials Mapping 536.1 Clinical Trials by Country (US, EU5 & Japan) 536.2 Clinical Trials by Phase 546.3 Clinical Trials by Trial Status 556.4 Prominent Sponsors 566.5 Key Companies Participating in Therapeutics Clinical Trials 587 Amyotrophic Lateral Sclerosis Therapeutics: Stategic Assessment 597.1 Key Events Impacting on the Future Market 597.2 Amyotrophic Lateral Sclerosis Therapeutics: Implications for Future Market Competition 598 Amyotrophic Lateral Sclerosis Therapeutics: Future Players 618.1 Introduction 618.2 Company Profiles 628.2.1 The Avicena Group Inc. 628.2.2 Biogen Idec/Knopp Bioscience Inc. 628.2.3 Actelion Pharmaceuticals Ltd. 648.2.4 Mitsubishi Tanabe Pharma Corporation 648.2.5 Eisai Co. Ltd 658.2.6 Other Companies in the Amyotrophic Lateral Sclerosis Therapeutics Market 679 Amyotrophic Lateral Sclerosis Therapeutics: Licensing and Partnership Deals 7210 Amyotrophic Lateral Sclerosis Therapeutics: Appendix 7410.1 Market Definitions 7410.2 Abbreviations 7410.3 Methodology 7510.3.1 Coverage 7610.3.2 Secondary Research 76Amyotrophic Lateral Sclerosis (ALS) Therapeutics - Pipeline Assessment and Market Forecasts to 2018 (From Slideshare) Page 3/8
  4. 4. Find Industry reports, Company profilesReportLinker and Market Statistics >> Get this Report Now by email!10.3.3 Forecasting 7610.3.4 Primary Research 7810.3.5 Expert Panel Validation 7810.4 Contact Us 7810.5 Disclaimer 7810.6 Bibliography 79List of TablesTable 1: Incidence of ALS in Top Seven Countries and the World 9Table 2: EI Escorial Criteria for Diagnosing ALS 11Table 3: Drugs for the Symptomatic Treatment of ALS 12Table 4: Amyotrophic Lateral Sclerosis Therapeutics Market, Global, Revenue($m), 2005-2010 18Table 5: Amyotrophic Lateral Sclerosis Therapeutics Market, Global, Forecast($m), 2010-2018 20Table 6: Amyotrophic Lateral Sclerosis Therapeutics Market, The US, Revenue($m), 2005-2010 20Table 7: Amyotrophic Lateral Sclerosis Therapeutics Market, The US, Forecast($m), 2010-2018 21Table 8: Amyotrophic Lateral Sclerosis Therapeutics Market, France, Revenue($m), 2005-2010 22Table 9: Amyotrophic Lateral Sclerosis Therapeutics Market, France, Forecast($m), 2010-2018 23Table 10: Amyotrophic Lateral Sclerosis Therapeutics Market, Germany, Revenue($m), 2005-2010 24Table 11: Amyotrophic Lateral Sclerosis Therapeutics Market, Germany, Forecast ($m), 2010-2018 25Table 12: Amyotrophic Lateral Sclerosis Therapeutics Market, Italy, Revenue ($m), 2005-2010 26Table 13: Amyotrophic Lateral Sclerosis Therapeutics Market, Italy, Forecast ($m), 2010-2018 27Table 14: Amyotrophic Lateral Sclerosis Therapeutics Market, Spain, Revenue ($m), 2005-2010 28Table 15: Amyotrophic Lateral Sclerosis Therapeutics Market, Spain, Forecast ($m), 2010-2018 29Table 16: Amyotrophic Lateral Sclerosis Therapeutics Market, UK, Revenue ($m), 2005-2010 30Table 17: Amyotrophic Lateral Sclerosis Therapeutics Market, UK, Forecast ($m), 2010-2018 31Table 18: Amyotrophic Lateral Sclerosis Therapeutics Market, Japan, Revenue ($m), 2005-2010 32Table 19: Amyotrophic Lateral Sclerosis Therapeutics Market, Japan, Forecast ($m), 2010-2018 33Table 20: Amyotrophic Lateral Sclerosis Therapeutics Phase III Clinical Pipeline, 2011 41Table 21: Amyotrophic Lateral Sclerosis Therapeutics Phase II Clinical Pipeline, 2011 41Table 22: Amyotrophic Lateral Sclerosis Therapeutics Phase l Pipeline, 2011 42Table 23: Amyotrophic Lateral Sclerosis Therapeutics Preclinical Pipeline, 2011 42Table 24: Amyotrophic Lateral Sclerosis Therapeutics Discovery Pipeline, 2011 43Table 25: Amyotrophic Lateral Sclerosis Therapeutics Phase Unknown, 2011 43Table 26:Amyotrophic Lateral Sclerosis Therapeutics Most Promising Drugs Under Development, 2011 46Table 27: A Brief History of dexpramipexole 47Table 28: A Brief History of olesoxime 49Table 29: Amyotrophic Lateral Sclerosis Therapeutics, Clinical Trials by Country,2011 53Table 30: Amyotrophic Lateral Sclerosis Therapeutics, Global, Clinical Trials by Phase of Development, 2011 54Table 31: Amyotrophic Lateral Sclerosis Therapeutics, Global, Clinical Trials by Trial Status, 2011 55Table 32: Amyotrophic Lateral Sclerosis Therapeutics, Global, Clinical Trials by Overall Sponsors, 2011 56Table 33: Amyotrophic Lateral Sclerosis Therapeutics, Global, Clinical Trials by Prominent Sponsors, 2011 57Table 34: Amyotrophic Lateral Sclerosis Therapeutics, Global, Clinical Trials by Top Companies, 2011 58Table 35: The Avicena Group Inc. - CNS Pipeline Portfolio, 2011 62Table 36: Biogen Idec. CNS Pipeline Portfolio, 2011 63Table 37: Knopp Bioscience Inc. CNS Pipeline Portfolio, 2011 63Table 38: Actelion Pharmaceuticals Ltd - CNS Pipeline Portfolio, 2011 64Table 39: Mitsubishi Tanabe Pharma Corporation CNS Pipeline Portfolio, 2011 65Amyotrophic Lateral Sclerosis (ALS) Therapeutics - Pipeline Assessment and Market Forecasts to 2018 (From Slideshare) Page 4/8
  5. 5. Find Industry reports, Company profilesReportLinker and Market Statistics >> Get this Report Now by email!Table 40: Eisai Co. Ltd. CNS Pipeline Portfolio, 2011 66Table 41: Other Companies in the Pipeline, 2011 67Table 42: Licensing and Partnership Deals, 2010-2011 72List of FiguresFigure 1: Normal and ALS-Affected Nerve Cells 7Figure 2: Normal and ALS affected Motor Neurons/Muscles 8Figure 3: Management Algorithm for Sialorrhea in Patients with ALS 13Figure 4: Management Algorithm for Nutrition Deficiency in Patients with ALS 14Figure 5: Management Algorithm for Respiratory Problems in Patients with ALS 15Figure 6: Amyotrophic Lateral Sclerosis Therapeutics, Referral Pathway 16Figure 7: Amyotrophic Lateral Sclerosis Therapeutics Market, Global, Revenue($m), 2005-2010 18Figure 8: Amyotrophic Lateral Sclerosis Therapeutics Market, Global, Forecast ($m), 2010-2018 19Figure 9: Amyotrophic Lateral Sclerosis Therapeutics Market, The US, Revenue($m), 2005-2010 20Figure 10: Amyotrophic Lateral Sclerosis Therapeutics Market, The US, Forecast($m), 2010-2018 21Figure 11: Amyotrophic Lateral Sclerosis Therapeutics Market, France, Revenue($m), 2005-2010 22Figure 12: Amyotrophic Lateral Sclerosis Therapeutics Market, France, Forecast($m), 2010-2018 23Figure 13: Amyotrophic Lateral Sclerosis Therapeutics Market, Germany, Revenue($m), 2005-2010 24Figure 14: Amyotrophic Lateral Sclerosis Therapeutics Market, Germany, Forecast ($m), 2010-2018 25Figure 15: Amyotrophic Lateral Sclerosis Therapeutics Market, Italy, Revenue ($m), 2005-2010 26Figure 16: Amyotrophic Lateral Sclerosis Therapeutics Market, Italy, Forecast ($m), 2010-2018 27Figure 17: Amyotrophic Lateral Sclerosis Therapeutics Market, Spain, Revenue ($m), 2005-2010 28Figure 18: Amyotrophic Lateral Sclerosis Therapeutics Market, Spain, Forecast ($m), 2010-2018 29Figure 19: Amyotrophic Lateral Sclerosis Therapeutics Market, UK, Revenue ($m), 2005-2010 30Figure 20: Amyotrophic Lateral Sclerosis Therapeutics Market, UK, Forecast ($m), 2010-2018 31Figure 21: Amyotrophic Lateral Sclerosis Therapeutics Market, Japan, Revenue ($m), 2005-2010 32Figure 22: Amyotrophic Lateral Sclerosis Therapeutics Market, Japan, Forecast ($m), 2010-2018 33Figure 23: Opportunity and Unmet Need in the Amyotrophic Lateral Sclerosis Therapeutics Market, 2010 35Figure 24: Strategic Competitor Assessment of the Major Marketed Products for Amyotrophic Lateral Sclerosis, 2011 37Figure 25: Amyotrophic Lateral Sclerosis Therapeutics, Molecular Structure of Rilutek 38Figure 26: Amyotrophic Lateral Sclerosis Therapeutics, Pipeline by Phase of Development, 2011 40Figure 27: Amyotrophic Lateral Sclerosis Therapeutics Market Pipeline by Mechanism of Action, 2011 44Figure 28: Technology Trends Analytic Framework of the Amyotrophic Lateral Sclerosis Therapeutics Pipeline, 2011 45Figure 29: Technology Trends Analytic Framework of the Amyotrophic Lateral Sclerosis Therapeutics Pipeline - Description, 2011 46Figure 30: Amyotrophic Lateral Sclerosis Therapeutics, Molecular Structure of dexpramipexole 47Figure 31: Amyotrophic Lateral Sclerosis Therapeutics, Molecular Structure of olesoxime 49Figure 32: Amyotrophic Lateral Sclerosis Therapeutics - Clinical Trials by Country, 2011 53Figure 33: Amyotrophic Lateral Sclerosis Therapeutics, Global, Clinical Trials by Phase of Development, 2011 54Figure 34: Amyotrophic Lateral Sclerosis Therapeutics, Global, Clinical Trials by Trial Status, 2011 55Figure 35: Amyotrophic Lateral Sclerosis Therapeutics, Global, Clinical Trials by Overall Sponsors, 2011 56Figure 36: Amyotrophic Lateral Sclerosis Therapeutics, Global, Clinical Trials by Prominent Sponsors, 2011 57Figure 37: Amyotrophic Lateral Sclerosis Therapeutics, Global, Clinical Trials by Top Companies, 2011 58Figure 38: Amyotrophic Lateral Sclerosis Therapeutics Market, Drivers and Barriers, 2011 59Figure 39: Implications for Future Market Competition in the Amyotrophic Lateral Sclerosis Therapeutics Market, 2011 59Figure 40: Amyotrophic Lateral Sclerosis Therapeutics Clinical Pipeline by Company, 2011 61Companies MentionedAmyotrophic Lateral Sclerosis (ALS) Therapeutics - Pipeline Assessment and Market Forecasts to 2018 (From Slideshare) Page 5/8
  6. 6. Find Industry reports, Company profilesReportLinker and Market Statistics >> Get this Report Now by email!The Avicena Group Inc.Biogen Idec/Knopp Bioscience Inc.Actelion Pharmaceuticals Ltd.Mitsubishi Tanabe Pharma CorporationEisai Co. LtdAmyotrophic Lateral Sclerosis (ALS) Therapeutics - Pipeline Assessment and Market Forecasts to 2018 (From Slideshare) Page 6/8
  7. 7. Find Industry reports, Company profilesReportLinker and Market Statistics >> Get this Report Now by email! Fax Order Form To place an order via fax simply print this form, fill in the information below and fax the completed form to: Europe, Middle East and Africa : + 33 4 37 37 15 56 Asia, Oceania and America : + 1 (805) 617 17 93 If you have any questions please visit http://www.reportlinker.com/notify/contact Order Information Please verify that the product information is correct and select the format(s) you require. Amyotrophic Lateral Sclerosis (ALS) Therapeutics - Pipeline Assessment and Market Forecasts to 2018 Product Formats Please select the product formats and the quantity you require. 1 User License--USD 3 500.00 Quantity: _____ Site License--USD 7 000.00 Quantity: _____ Corporate License--USD 10 500.00 Quantity: _____ Contact Information Please enter all the information below in BLOCK CAPITALS Title: Mr Mrs Dr Miss Ms Prof First Name: _____________________________ Last Name: __________________________________ Email Address: __________________________________________________________________________ Job Title: __________________________________________________________________________ Organization: __________________________________________________________________________ Address: __________________________________________________________________________ City: __________________________________________________________________________ Postal / Zip Code: __________________________________________________________________________ Country: __________________________________________________________________________ Phone Number: __________________________________________________________________________ Fax Number: __________________________________________________________________________Amyotrophic Lateral Sclerosis (ALS) Therapeutics - Pipeline Assessment and Market Forecasts to 2018 (From Slideshare) Page 7/8
  8. 8. Find Industry reports, Company profilesReportLinker and Market Statistics >> Get this Report Now by email! Payment Information Please indicate the payment method, you would like to use by selecting the appropriate box. Payment by credit card Card Number: ______________________________________________ Expiry Date __________ / _________ CVV Number _____________________ Card Type (ex: Visa, Amex…) _________________________________ Payment by wire transfer Crédit Mutuel RIB : 10278 07314 00020257701 89 BIC : CMCIFR2A IBAN : FR76 1027 8073 1400 0202 5770 189 Payment by check UBIQUICK SAS 16 rue Grenette – 69002 LYON, FRANCE Customer signature:   Please note that by ordering from Reportlinker you are agreeing to our Terms and Conditions at http://www.reportlinker.com/index/terms Please fax this form to: Europe, Middle East and Africa : + 33 4 37 37 15 56 Asia, Oceania and America : + 1 (805) 617 17 93Amyotrophic Lateral Sclerosis (ALS) Therapeutics - Pipeline Assessment and Market Forecasts to 2018 (From Slideshare) Page 8/8

×